Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 335

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 335
---
Item 1. Financial Statements.

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share data)

 June 30,2025December 31,2024 (Note 2) AssetsCurrent assets:Cash and cash equivalents$228,122 $222,503 Short-term investments76,430 57,812 Accounts receivable106,836 78,286 Inventory22,941 22,403 Prepaid expenses and other current assets19,069 11,784 Total current assets453,398 392,788 Restricted cash480 425 Long-term investments17,112 12,526 Property and equipment, net1,177 1,139 Operating lease right-of-use assets8,946 8,675 Intangible assets, net237,870 249,819 Other assets6,842 5,382 Total assets$725,825 $670,754 Liabilities and Stockholders’ EquityCurrent liabilities:Accounts payable$17,657 $14,618 Accrued expenses and other current liabilities127,139 111,933 Total current liabilities144,796 126,551 Operating lease liabilities, noncurrent7,884 7,972 Convertible notes payable, net, noncurrent308,933 308,082 Other liabilities9,054 2,509 Total liabilities470,667 445,114 Commitments and contingenciesStockholders’ equity:Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of June 30, 2025 and December 31, 2024— — Common stock, $0.0001 par value; 200,000,000 shares authorized; 50,058,392 and 48,338,096 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively5 5 Additional paid-in capital919,520 870,189 Accumulated deficit(664,719)(644,181)Accumulated other comprehensive income (loss)352 (373)Total stockholders’ equity255,158 225,640 Total liabilities and stockholders’ equity$725,825 $670,754 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1

Table